IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

A. Socinski, Mark; Nishio, Makoto; M. Jotte, Robert; Cappuzzo, Federico; Orlandi, Francesco; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez‐Abreu, Delvys; Moro‐Sibilot, Denis; A. Thomas, Christian; Barlési, Fabrice; Grant Finley, Gene; Kong, Shengchun; Lee, Anthony; Coleman, Shelley; Zou, Wei; L. McCleland, Mark; Shankar, Geetha; Reck, Martin

doi:10.1016/j.jtho.2021.07.009

Public

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Published in Journal of Thoracic Oncology • Jul 24, 2021

Authors:

Mark A. Socinski

Makoto Nishio

Robert M. Jotte

Abstract

INTRODUCTION: We report the final overall survival (OS) analyses of atezolizumab-carboplatin-paclitaxel (ACP [experimental arm]) and OS data with approximately 39.8 months of median follow-up with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) versus bevacizumab-carboplatin-paclitaxel (BCP) ...

Subject

Atezolizumab

Medicine

Bevacizumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!